^
CANCER:

Small Intestinal Carcinoma

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab
Sensitive
:
A1
NTRK3 fusion
Small Intestinal Carcinoma
entrectinib
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
gemcitabine + docetaxel
Sensitive
:
A2
NTRK1 fusion
Small Intestinal Carcinoma
entrectinib
Sensitive
:
A2
NTRK2 fusion
Small Intestinal Carcinoma
entrectinib
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
LV5FU2
Sensitive
:
A2
MSI-H/dMMR
Small Intestinal Carcinoma
nivolumab
Sensitive
:
A2
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab + ipilimumab
Sensitive
:
A2
MSI-H/dMMR
Small Intestinal Carcinoma
nivolumab + ipilimumab
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
FOLFOX
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
CAPOX
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
bevacizumab
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
capecitabine
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
5-fluorouracil
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
irinotecan
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
FOLFIRI
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
docetaxel
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
paclitaxel
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
paclitaxel + gemcitabine
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
carboplatin + paclitaxel
Sensitive
:
A2
NTRK1 fusion
Small Intestinal Carcinoma
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Small Intestinal Carcinoma
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Small Intestinal Carcinoma
larotrectinib
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
GTX
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
FOLFIRINOX
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
mFOLFOX6
Sensitive
:
A2
MSI-L/dMMR
Small Intestinal Carcinoma
dostarlimab
Sensitive
:
A2
RET fusion
Small Intestinal Carcinoma
selpercatinib
Sensitive
:
C1
PTEN mutation + MSI-H/dMMR
Small Intestinal Carcinoma
PD1 inhibitor
Resistant
:
C3
MSI-H/dMMR + TMB-L
Small Intestinal Carcinoma
PD1 inhibitor
Resistant
:
C3